b-catenin, an oncogene, and P53, a tumor suppressor, are common targets of mutation in human cancers. It has been observed that P53 is often inactivated in tumors involving b-catenin activation. In an attempt to model this situation in vivo, we crossed the previously characterized MMTV-DN-b-catenin mouse with the P53 knockout mouse. Female multiparous mice that carry the MMTV-DN-bcatenin transgene and that are heterozygous for P53 (Tg 
Introduction b-catenin carries out multiple distinct functions within a cell. In one capacity b-catenin participates as the effector molecule in the Wnt signal transduction pathway (reviewed in Polakis, 2000; Smalley and Dale, 2001; Hatsell et al., 2003) . b-catenin levels are regulated in the cell by the APC/Axin/GSK3b complex (Behrens et al., 1998; Ikeda et al., 1998; Kishida et al., 1998) . In resting cells, GSK3b phosphorylates b-catenin at sites in its N-terminus initiating a cascade of events that result in ubiquitylation and subsequent degradation. In response to extracellular Wnt, a signal is transduced through the Frizzled receptor to disheveled leading to disruption of the b-catenin/APC/Axin/GSK3b complex. Subsequently, b-catenin accumulates and enters the nucleus where it associates with Tcf/Lef transcription factors and activates target genes (Behrens et al., 1996; Molenaar et al., 1996; Brunner et al., 1997; van de Wetering et al., 1997) . Aberrant stabilization of bcatenin is observed in a variety of cancers, owing to mutations in APC, Axin or within b-catenin itself that result in a block of GSK3b phosphorylation and prevent the degradation cascade. (Polakis, 2000) .
b-catenin regulates the expression of a number of genes linked to cancer, including c-Myc and cyclin D1 (He et al., 1998; Tetsu and McCormick, 1999) . b-catenin is stabilized in 50% of human breast carcinomas and the elevated levels of b-catenin correlate with increased cyclin D1 expression and poor prognosis (Lin et al., 2000; Ryo et al., 2001) . Furthermore, in lymph node negative breast tumors, the presence of high levels of b-catenin protein in combination with high levels of P53 protein correlated with poor survival of patients (Chung et al., 2004) , indicating that b-catenin and P53 may have a combinatorial effect on tumor progression. In addition to the human data, studies using mouse models have demonstrated a role for b-catenin in initiating mammary tumors (Imbert et al., 2001; Michaelson and Leder, 2001) .
P53 is a tumor suppressor molecule mutated in 50% of all human cancers (Hainaut et al., 1998) . The P53 pathway responds to a variety of intrinsic and extrinsic stress signals and when activated maintains cellular integrity by inducing cell cycle arrest, senescence or apoptosis (reviewed in (Harris and Levine, 2005) ). Recently, it has been shown that b-catenin and P53 form a negative feedback loop that regulates Wnt signaling. b-catenin induces P53 activation by inducing P19 ARF expression, P19 ARF inhibits Mdm2 and consequently leads to an accumulation of active P53 (Damalas et al., 1999 (Damalas et al., , 2001 . In primary mouse fibroblasts this pathway induces growth inhibition and replicative senescense in response to the overexpression of an activated form of b-catenin (Damalas et al., 2001) . In addition to this growth inhibitory function, P53 activation initiates a negative feedback loop. P53 promotes proteolysis of b-catenin through activation of two separate ubiquitylation complexes. P53 effects Axin dynamics and increases the activity of the traditional APC/Axin/GSK3b complex thereby increasing the degradation rate of b-catenin (Levina et al., 2004) . In addition, P53 induces the expression of a member of the Siah-1 family, Siah-1L, which forms a complex with SIP and Ebi resulting in ubiquitylation and degradation of b-catenin (Liu et al., 2001; Matsuzawa and Reed, 2001; Sadot et al., 2001) . The existence of specific feedback loops involving P53 and b-catenin is intriguing given the high incidence of mutation in P53 in human colorectal cancers harboring aberrant b-catenin signaling (Kinzler and Vogelstein, 1996) .
b-catenin signaling has recently been linked to the process of stem cell renewal (reviewed in (Brennan and Brown, 2004) ). In the hematopoietic system, Wnt/ b-catenin signaling maintains cells in a pluripotent proliferative state (Willert et al., 2003) . Similar findings were found in human embryonic stem cells where inhibition of GSK3b and subsequent b-catenin stabilization maintained the pluripotency of the cells in culture (Sato et al., 2004) . During Wnt-induced transformation of mammary tissue this link to stem cell renewal is thought to result in preferential accumulation and induction of cancer from mammary progenitor cells (Li et al., 2003) . Taken together, these findings imply that Wnt/b-catenin signaling is an important normal process in the proliferation and renewal of stem cells and that aberrant b-catenin regulation may simulate a stem cell-like proliferation, leading to uncontrolled proliferation and tumor formation. In the present study, we investigated the consequence of mutating one P53 allele on the mammary tumor phenotype observed in the MMTVDNb-catenin mouse. Female animals carrying only one functional P53 allele display an increased tumor burden and develop mammary tumors that are more malignant, invasive, and metastatic than females carrying two functional P53 alleles. The differences observed in these two backgrounds are a consequence of losing a single copy of P53 because we did not observe mutation or loss of heterozygosity (LOH) in the remaining wild-type allele in these tumors. In addition, we developed a novel animal model in which to study testicular teratomas and identify a synergistic role between b-catenin and P53 in development of these germ cell tumors.
Results

Pathology of mammary tumors
In order to determine whether P53 plays a specific role in protecting the mammary gland from transformation by b-catenin, mammary tumors derived from Tg
were compared in multiparous and virgin cohorts. The mice in this study were maintained on a pure FVB background and as such non-Tg DN-bCat , P53 þ /À mice do not develop mammary tumors and we did not observe any mammary tumors in any of our P53 þ /À control animals. Females in the multiparous cohorts were mated continuously from 8 to 10 weeks of age until sacrifice. As previously described (Michaelson and Leder, 2001) , Tg DN-bCat / þ , P53 þ / þ developed mammary tumors around 13 months of age for multiparous females and after 15 months of age for virgin females. Tumors in these animals are microacinar adenocarcinomas (Figure 1a and b) and have been described previously (Michaelson and Leder, 2001) . Only 2 of 12, Tg P53 þ /À virgin females developed mammary tumors. The other 10 animals developed an array of tumors typical in P53 þ /À animals around 12 months of age, including rhabdomyosarcomas, osteosarcomas, and lymphomas. (Donehower et al., 1992 (Donehower et al., , 1995b . The mammary tumors that did develop in the Tg DNbCat / þ , P53þ /À virgin cohort tended to be similar to the Tg (Figure 1a and b) and contained mainly microacinar structures with regions of disorganized tissue and some invasiveness (data not shown). As previously reported for other MMTV transgenes crossed to the P53 þ /À background (Hundley et al., 1997; Brodie et al., 2001) , the Tg 
In general, these tumors appear pathologically less differentiated, more malignant and more invasive than either Tg / þ , P53 þ /À multiparous females were often fast growing tumors displaying fluid filled necrotic cores, tumor boundaries containing highly disorganized structures with a high degree of pleiomorphic nuclei, many mitotic figures and extensive areas of invasiveness (Figure 1c and d) . This data suggests that P53 levels can influence the growth rate and pathological appearance of b-catenin-induced tumors.
In order to determine a cause for the increased growth rate and invasiveness of the tumors in P53 þ /À mice, we looked at the numbers of proliferating cells, using immunohistochemistry (IHC) against proliferating cell nuclear antigen (PCNA), and the numbers of apoptotic cells, using a standard TUNNEL assay. Neither assay indicated any differences between Tg DN-bCat / þ , P53 þ /À and Tg
Increased tumor numbers and metastases in P53 þ /À animals Previous studies reported that a number of the Tg DN-bCat / þ , P53 þ / þ animals in their cohort developed multiple independent tumors (Michaelson and Leder, 2001 ). In our cohorts, 28% of the animals from the Tg Figure 1 (e). These findings suggest that loss of one allele of P53, whereas not significantly affecting the time it takes for tumor development, does affect the number of independent events leading to transformation, resulting in more tumors developing.
In addition to developing a greater number of tumors per animal, Tg (Table 1 ). In all, seven out of 18 animals (39%) that developed mammary tumors in the Tg
background presented with lung metastases at the time of killing. The lungs in each case presented with multiple regions of invasive tumor cells that appeared to be mammary adenocarcinoma. An example of an hematoxylin and eosin (H&E) stained section identifying a lung metastasis is shown in Figure 2c compared to the primary tumor shown in Figure 2a . We carried out IHC on sections from primary and metastatic tumors, using an anti-b-catenin antibody in order to determine whether the lung metastases arose from our primary tumors. As shown in Figure 2 , the primary tumor and the metastasis both stain strongly for b-catenin ( Figure  2b and d). Although the antibody identifies endogenous b-catenin in addition to the transgene, the high level of staining and the presence of b-catenin in the cytoplasm and nucleus (Figure 2d inset) suggests that these metastases express the transgene. Further, we carried out IHC on these sections using an anti-estrogen receptor-a antibody. Both the primary tumors and metastases express estrogen receptor-a (ERa) in the nuclei of the tumor cells (data not shown). Taken together, these results strongly suggest that the lung tumors found in Tg DN-bCat / þ , P53 þ /À mice are metastases arising from the primary mammary tumors. In comparison, the Tg
P53 mutational status in tumors
Given the fact Tg DN-bCat / þ , P53 þ /À mice displayed increased tumor formation and metastasis, we hypothesized that the single remaining P53 allele was a candidate for mutation in these tumors. In order to address this issue, P53 LOH was examined in 21 / þ , P53 þ /À females, such as the rhabdomyosarcomas and lymphomas, these tumors always displayed LOH at the wild-type allele (data not shown).
In order to further characterize the remaining wildtype allele and to identify any mutations arising in the tumors, the P53 gene was sequenced in 35 tumors arising in our Tg
Primers within exons 1 and 6 were used to amplify the 5 0 region of the gene and primers in exons 4 and 10 to amplify the 3 0 region of the gene. Utilizing this strategy we were able to cover the first 343 amino acids of the protein. The vast majority of mutations in P53 are point mutations arising within the central region of the protein between amino acids 102 and 292 (Slee et al., 2004) . No point mutations were observed in any of the mammary tumors examined, indicating that the tumors not only retain the wild-type allele but that this allele is functional. This suggests that in the context of a mammary tumor induced by expression of the MMTV-b-catenin transgene, loss or mutation of the wild-type allele is not required for tumor formation. P53 status in metastatic tumors was not assessed. Therefore, the possibility that the cells that are capable of surviving the migration to a distant site have mutated the wildtype P53 allele cannot be excluded.
Testicular teratomas in the P53À/À background
In addition to examining the effect of mutating one allele of P53 on mammary tumor development, the effects of deleting both alleles of P53 in the MMTVDNb-catenin background was examined. Female mice null for P53, whether they carried the b-catenin transgene or not, lived approximately 100 days with no animals living longer than 120 days (Figure 4) . We did not observe any differences between females carrying the transgene, Tg DNbCat / þ , P53À/À and females not carrying the transgene, non-Tg DNbCat , P53À/À, in either survival or tumor spectrum. As expected for these animals, lymphomas and/or hemangiosarcomas were the major causes of death in these animals (Donehower et al., 1992) . Consequently, the female P53À/À did not live long enough for mammary tumors to develop and were not studied in that regard.
In male P53À/À mice a transgene dependent phenotype was observed. As shown in Figure 4 , Tg DN-bCat / þ , P53À/À males had a significantly shorter lifespan than non-Tg DN-bCat , P53À/À males (65 days vs 84 days, w 2 ¼ 11.48, P ¼ 0.0007). This shortened lifespan is the direct result of the Tg DN-bCat / þ , P53À/À males developing testicular teratomas (Figure 4b-d) . The tumors arising in these mice contain various degrees of differentiated tissue that arise from all three germ layers, such as muscle, brain, cartilage, bone, squamous and columnar epithelium and other tissues. In total, 15 of 24 Tg DN-bCat / þ , P53À/À male mice developed testicular teratomas with five of these animals developing bilateral tumors (Table 2) . By comparison, in only two of 20 non-Tg DN-bCat , P53À/À male mice did teratomas arise (Table 2 ). The increase in incidence to 62.5% of males in the Tg DN-bCat / þ , P53À/À cohort indicates that the MMTV-DNb-catenin transgene is capable of synergizing with P53 mutation in transforming male germ cells.
MMTV promoter is expressed in the testes
The MMTV promoter is expressed in tissues other than the mammary gland. In particular, early work with the mouse mammary tumor virus identified virus particles in the testes of male mice infected by the virus (Kozma et al., 1980; Henrard and Ross, 1988) . To determine if the MMTV-DNb-catenin transgenic animals expressed activated b-catenin in the testes, transgene expression was evaluated by RT-PCR. Primers were chosen in the 3 0 region of the b-catenin open reading frame and the 5 0 region of the SV40 polyA tail sequence used in the transgene (Figure 5a ) so as to be specific for only the MMTV-DNb-catenin transgene. Analysis of RNA isolated from the testes of 8-week-old mice is shown in Figure 5b . Non-Tg (Figure 5b, lanes 3 and 7) . Interestingly, no testicular teratomas were found in the 24 Tg DN-bCat / þ , P53 þ /À male mice monitored for up to 18 months of age. The lack of teratomas in P53 þ /À mice indicates that one copy of the wild-type P53 allele was sufficient for protecting male germ cells from transformation owing to aberrant expression of b-catenin.
Tg
DN-bCat
/ þ , P53À/À teratomas expressed the b-catenin transgene and the downstream target cyclin D1 In order to determine whether or not transgene expression was maintained in the teratomas, RT-PCR was performed on RNA isolated from teratomas arising in Tg DN-bCat / þ , P53À/À mice and non-Tg
, P53À/À mice ( Figure 5c ). All four of the Tg DN-bCat / þ , P53À/À teratomas represented in Figure 5c expressed the b-catenin transgene (Figure 5c, lanes 1, 3, 5 and 7) , whereas the teratoma from a non-Tg DN-bCat , P53À/À male did express the transgene (Figure 5c, lane 9) . These results indicate that in addition to being expressed in the testes, the b-catenin transgene was expressed in the teratomas despite the fact that the cells in these tumors differentiated into tissue that would not be expected to activate the MMTV promoter, such as brain.
To further establish the role of the b-catenin transgene in these tumors, IHC was performed to examine the expression of b-catenin and one of its established transcriptional targets, cyclin D1, in the teratomas. Upon sectioning a testicle from a Tg DN-bCat / þ , P53À/À male that appeared at autopsy to be disease free, an early lesion was identified upon examining the H&E stained section (Figure 5d ). This early lesion was used to examine b-catenin and cyclin D1 expression. Mosaic expression was observed for b-catenin, both in epithelial-like cells as well as less differentiated cells within this lesion (Figure 5e ). Mosaic expression was also observed for cyclin D1 in this lesion in many different cells (Figure 5f ). These findings suggest that upon transformation, b-catenin was continually highly expressed in a subset of cells within the tumor and that 
(b-d) H&E staining of sections from three teratomas that developed in the Tg
DNbCat / þ , P53À/À male mice. P53 affects b-catenin-induced tumorigenesis AG Ridgeway et al cyclin D1 was being upregulated and contributing to the transformed phenotype.
Discussion
We have generated a model to study the relationship between deregulated b-catenin signaling and the P53 pathway in vivo. In this model, female mice carrying only a single copy of P53 are burdened with more tumors per animal and these tumors are more malignant, invasive and progress to a metastatic state, than tumors arising in mice with two functional P53 alleles. These later mice often develop only a single tumor and do not progress to metastatic disease. Such differences in tumorigenesis within the mammary gland in P53 þ /À mice appear to be due to haploinsufficiency of P53 since the remaining wild-type allele in these tumors is neither lost nor mutated. This finding of haploinsufficiency in mammary epithelial cells is in contrast to the findings in the germ cells of male mice where mutation of both P53 alleles is required for testicular teratoma formation in b-catenin transgenic animals. Sixty-two percent of the animals in Tg DNbCat / þ , P53À/À background developed testicular teratomas, whereas this phenotype is not observed in P53 þ /À animals indicating that germ cells are more sensitive to P53 than mammary epithelial cells. These results identify a tumor-specific difference for the requirement of P53 mutation.
b-catenin's transformation activity is linked to its ability to upregulate downstream target genes associated with cell cycle progression, including c-myc, and cyclin D1. However, in addition to regulating the expression of these oncogenes, b-catenin increases the activity of P53 by inducing P19 ARF expression (Damalas et al., 1999 (Damalas et al., , 2001 . This increase in P53 activity stimulates two independent feedback loops, acting through Axin/APC/ GSK3b and Siah-1/SIP/Ebi, to degrade b-catenin and attenuate its signaling (Liu et al., 2001; Matsuzawa and Reed, 2001; Sadot et al., 2001; Levina et al., 2004) . However, each of these feedback loops require functional APC and binding to the N-terminal region of b-catenin. In many human cancers involving stabilization of b-catenin, either APC or b-catenin itself is mutated. In the case of APC mutation, neither the Axin/APC/ GSK3b nor the Siah-1/SIP/Ebi feedback loop will function. In the case of point mutations in the phosphorylation sites of b-catenin, only the Siah-1/ SIP/Ebi loop will induce degradation of b-catenin. In our model, the entire N-terminal region of b-catenin has been removed; therefore, neither feedback loop will function to degrade this stabilized form of the molecule, as would be the case in many human cancers. Therefore, only the traditional downstream functions of P53 will be involved in regulating tumorigenesis in this model.
Loss of P53 is associated with dramatic genomic instability and as a result increased mutational events in tumors (Donehower et al., 1995b; Venkatachalam et al., 1998) . Given the long latency of tumor initiation in our stochastic MMTV-DNb-catenin mice, we expect that secondary mutation is essential for tumorigenesis in this model. Therefore, p53 was an excellent candidate for this mutation. It is surprising that LOH at the wild-type P53 allele was observed in only one of 21 tumors because the single copy of P53 is sufficient to maintain genomic integrity (Donehower et al., 1995b; Venkatachalam et al., 1998) . Interestingly, in the case of b-catenin-induced tumors, LOH occurs less frequently (only 4.5% of tumors) than in MMTV-Wnt1, P53 þ /À mice (50% of tumors) or Wnt1 inducible, P53 þ /À mice (19% of tumors) (Donehower et al., 1995a; Gunther et al., 2003) . This difference may be partly due to the presence of intact b-catenin degradation machinery in these models, resulting in pressure to select mutated P53 alleles not present in the MMTV-DNb-catenin model.
In the case of MMTV-DNb-catenin-induced tumors, mutating one allele of P53 was sufficient to alter the pathogenesis of the tumors arising in these mice. Although tumors arose at a similar rate in the P53 þ /À and P53 þ / þ animals, a major difference was identified in tumor burden and metastatic progression. The P53 þ /À animals developed more tumors per animals (2.05 vs 1.31) and the tumors in these mice were metastatic in seven out of 18 animals. As genomic instability is not likely to occur in these tumors, other functions of P53 may be affected by losing a single copy of the gene. The cell cycle regulation and apoptotic functions of P53 may be more sensitive to changes in overall levels of the protein and therefore less likely to be fully functional in a P53 þ /À cell. Although we did not observe significant differences in the numbers of proliferating cells in Tg DN-bCat / þ , P53 þ /À compared to Tg DN-bCat / þ , P53 þ / þ primary tumors we cannot rule out the possibility that the cells are progressing through the cell cycle at a faster rate in Tg DN-bCat / þ , P53 þ /À tumors. Evidence for this is suggested by examining tumors in P53 þ /À mammary glands compared to wildtype tumors and the metastatic phenotypes of tumors observed in various genetic backgrounds. Tg DNbCat / þ , P53 þ /À tumors often presented with necrotic, fluid filled central cores not seen in the P53 þ / þ animals implying that these tumors grow quickly and may not be capable of maintaining a sufficient blood supply to the central regions of the tumor (data not shown). These results were similar to the findings of Jones et al. (1997) . who found that WntI-induced tumors in a P53 þ /À background grew faster than WntI-induced tumors in a P53 þ / þ background (Jones et al., 1997) . Additionally, in our model 39% of the Tg DNbCat / þ , P53 þ /À animals display lung metastases. This was similar to the level found in the Wnt1 inducible system where 30% of the animals in the P53 þ /À background displayed metastases (Gunther et al., 2003) . Although we do not observe a decrease in the number of apoptotic cells within the primary tumors of Tg
þ / þ mice we cannot rule out the possibility that migrating cells survive more easily in the Tg DN-bCat / þ , P53 þ /À background due to impaired apoptosis induction. Studies utilizing a c-Myc-induced lymphoma demonstrated that the defect resulting from loss of P53 that is responsible for enhancing metastasis is attributable to a lost apoptotic induction (Schmitt et al., 2002) . Furthermore, overexpression of anti-apoptotic molecules in mammary tumors can enhance metastasis from primary tumors that do not normally metastasize (Martin et al., 2004) . Therefore, we conclude from our findings that P53 haploinsufficiency impaired the cell cycle and apoptotic functions of the P53 pathway allowing tumors to grow faster and metastasize.
The findings we observed in the mouse are consistent with data obtained with human breast cancer patients. Chung et al. (2004) observed that the presence of high levels of b-catenin protein in combination with high levels of P53 in the primary tumors of lymph node negative breast cancer patients correlated with a worse survival than patients displaying high levels of either protein alone. Given the role of P53 in apoptosis, observing high levels of P53 in a pathology sample is indicative of mutation in the P53 apoptotic pathway. Therefore, the findings of Chung et al. (2004) are consistent with our results that the combination of aberrant b-catenin and dysfunctional P53 leads to a more aggressive and metastatic tumor. These results have important implications related to the usefulness of multiple prognostic markers when analyzing tumors in the clinic.
Interestingly, in addition to the mammary tumor phenotype expected in the MMTV-DNb-catenin animals, a role for b-catenin in transformation of male germ cells was identified. Male mice from the Tg DN-bCat / þ , P53À/À background showed a six-fold increase in their propensity to develop testicular teratomas (Table 1) . This phenotype was only observed in mice null for P53, indicating that P53 plays an important role in maintaining cellular integrity in the germ cells of males.
P53 plays an important role in maintaining germ cell quality during spermatogenesis in young male mice (Yin et al., 1998) . Furthermore P53 is important for the proper occurrence of two waves of apoptosis during spermatogenesis, occurring at E16.5 and at 14 days postpartum (Rodriguez et al., 1997) . These apoptotic waves are thought to establish the correct cell numbers in the seminiferous tubules and remove any cells that have acquired mutations owing to the rapid proliferation that occurs during the initial wave of spermatogenesis. Mutation of P53 results in a lack of germ cell quality maintenance and abolition of the normal apoptotic waves, which may allow cells to survive that have acquired mutations and would normally be destroyed. These aberrant cells may be the precursors of the teratomas seen in the P53À/À background.
Pioneering work by Leroy Stevens established fundamental information regarding testicular germ cell tumors including the cell of origin, primordial germ cells; the anatomical location, the testes; and the developmental period; embryonic day 11.5-12.5 during which the testicular germ cell tumors (TGCT) originate (Stevens and Mackensen, 1961; Stevens, 1967) . The model of TGCT initiation proposes that primordial germ cells abnormally proliferate in the genital ridge, when they would normally arrest in G1. This aberrant proliferation results in the accumulation of pluripotent stem cells that progress to form tumors (Stevens and Mackensen, 1961) . This phenotype is accentuated in P53À/À mice (Harvey et al., 1993) and b-catenin is present in the cytoplasm of the majority of immature germ cells in males in the second and third trimester of development (Honecker et al., 2004) . Additionally, b-catenin activity is capable of maintaining an undifferentiated state in teratomas, implying that b-catenin signaling may push germ cells towards a proliferative undifferentiated state (Kielman et al., 2002) . This finding agrees with the work of many studies that uncovered a role for b-catenin in stem cell maintenance (Li et al., 2003; Willert et al., 2003; Liu et al., 2004; Sato et al., 2004) .
Although we were unable to directly observe expression of the b-catenin transgene due to its low level of expression in the germ cells of male mice, the MMTV promoter is expected to be active at a low level in the testes of male mice (Kozma et al., 1980; Henrard and Ross, 1988) . Therefore, our results suggest that low-level expression of the DNb-catenin transgene in the testes may exert additional pressure on germ cells, stimulating aberrant proliferation of cells that should arrest in G1. In combination with the absence of P53, a six-fold increase in the number of teratomas was observed in males expressing the b-catenin transgene. Therefore, bcatenin signaling is sufficient to induce aberrant growth of the germ cells mutant for P53.
In summary, we utilized the MMTV-DNb-catenin transgenic mouse and the P53 knockout mouse to further characterize the relationship between these two important molecules in human cancer. Loss of a single P53 allele in the context of mammary tumors is sufficient for these tumors to be more malignant and metastatic than mice carrying two copies of P53. This haploinsufficient effect appears to be due to differences in cell cycle control and apoptosis regulation as opposed to genomic instability. Additionally, a novel model for examining testicular teratomas has been identified. This model indicates that b-catenin signaling is able to induce teratomas in P53 mutant cells. Furthermore, this model suggests that P53 loss has varying effects on cells in different tissues. A single copy of the P53 gene is sufficient for blocking tumorigenesis in male germ cells, whereas this is not the case in mammary epithelium. This finding suggests that the germ cells are programmed to be more sensitive to P53 than other tissues, potentially as a mechanism to protect the integrity of the genome for future generations.
Materials and methods
Animal cohorts MMTV-DNb-catenin animals (Michaelson and Leder, 2001) and P53 knockout mice (Donehower et al., 1992) have been carried on the FVB background for many years. In order to produce animals of the appropriate genotypes, heterozygous Tg DN-bCat / þ were crossed to P53 þ /À mice to generate double heterozygous animals Tg DN-bCat / þ , P53 þ /À. Double heterozygous animals were crossed with P53 þ /À animals to generate all experimental genotypes in the cohort:
, P53 þ /À and non-Tg DN-bCat , P53À/À. Specific genotypes were selected for various tumor cohorts and animals were monitored three times per week for tumors and killed either when tumors began to impede quality of life as directed by the veterinary staff. During autopsy, tissue from tumors and normal tissue was fixed for sectioning (below) or snap frozen in liquid N 2 .
Tissue preparation and histology Upon dissection, tissue was fixed in 10% neutral buffered formalin for 24 h followed by postfixation in 70% EtOH before being imbedded in paraffin and cut into 5 mm sections. Sections were stained with H&E or used for IHC. H&E sections were examined by Dr Roderick Bronson in the Harvard Medical School, mouse histopathology core facility.
IHC and tunnel assay
Formalin fixed, paraffin embedded sections were deparaffinized with xylene and alcohol. For b-catenin staining, epitope retrieval was carried out by boiling in 10 mM Sodium Citrate, 0.05% Tween-20, pH 6.0 for 20 min followed by cooling at room temperature for 20 min. b-Catenin primary antibody (BD Transduction Laboratories, cat. #:C19220) (1:50 dilution) was used in the DAKO ARK Peroxidase kit (Dako, cat. #:K3954) according to the manufacturers protocol. For Cyclin D1 staining, epitope retrieval was carried out by boiling in 10 mM Tris, 1 mM EDTA, 0.05% Tween-20, pH 9.0 for 20 min followed by cooling at room temperature for 20 min, followed by serum blocking in goat serum for 30 min. Cyclin-D1 primary antibody SP4 (NeoMarkers, cat. #:RM-9104) (1:50 dilution) and ERa primary antibody MC-10 (Santa Cruz, cat. #:sc-542) (1:150 dilution) were incubated for 1 h at room temperature followed by peroxidase blocking (3% H 2 O 2 in PBS) for 30 min at room temperature, and incubation in secondary goat anti-rabbit IgG (Vector Laboratories, Cat. #:BA-1000) (1:250 dilution) for 1 h at room temperature. PCNA primary antibody PC-10 (Santa Cruz, cat. #:sc-56) (1:2000 dilution) was incubated for 1 h at room temperature followed by peroxidase blocking (3% H 2 O 2 in PBS) for 30 min at room temperature, and incubation in secondary horse anti-mouse IgG (Vector Laboratories, cat. #:BA-2000) (1:500 dilution) for 1 h at room temperature. TUNNEL assays were carried out using recombinant terminal transferase from Roche (Cat. #3 33 574) and Biotin-16-UTP (Roche, cat. #11 093 070 910).
RNA isolation, and RT-PCR for transgene expression RNA from tumors or testes was isolated from snap frozen tissue using Trizol s Reagent (Gibco BRL, Cat. #:15596-026) according to the manufacturer's protocols. cDNA was prepared from tumor RNA using the Superscript III FirstStrand kit (Invitrogen, Cat. #:18080-051) according to the manufacturer's protocol for oligo-dT priming. PCR was performed on the resulting cDNA using Platinum Pfx polymerase (Invitrogen, Cat. #:11078-013) with primers designed specifically against the MMTV-b-catenin transgene. The upstream primer lies within the C-terminus region of the b-catenin open reading frame 5 0 -TGCCCCCAGGTGATAGC and the downstream primer lies within the SV40 polyA tail 5 0 -TTTGGAGGAGTAGAATGTTGAGAG.
P53 LOH
High molecular weight DNA was isolated from snap frozen tumor tissue to ascertain the status of the p53 wild-type allele. P53 LOH was assessed by Southern Blot hybridization of BamHI-cleaved tumor DNAs with a murine exon 2-6 p53 cDNA probe made by digesting the p53 open reading frame cDNA with KpnI and XhoI. Southern blots were visualized with Kodak BioMax Light Film and by using a phosphorimager for quantification of band intensity (Molecular Devices ImageQuant Software). LOH was determined to have occurred in a tumor if the intensity of the wild-type band was less than 50% of the intensity of the mutant band. Cross hybridization to the pseudogene was used as a loading/probing internal control.
P53 mutation analysis RT-PCR was carried out as described above for generating P53 cDNA. Two primer sets were used to amplify the entire open reading frame. The first set consisted of primer: 5 0 -CAC GTGCTCACCCTGGCTAAAAGT-3 0 and primer: 5 0 -CTGT CTTCCAGATACTCGGGATAC-3 0 that amplify from exons 1-6; the second set consisted of primer: 5 0 -GGGACAGCCA AGTCTGTTATGTGC-3 0 and primer: 5 0 -CTCCCGGAACA TCTCGAAGC-3 0 that amplify from exons 4-10 (Donehower et al., 1992) . P53 cDNA was sequenced using the same primers used for amplification.
